TP53 and acute myeloid leukemia: Mice injected with control T-cells showed rapid AML progression as determined by bioluminescence imaging and had to be sacrificed within 3 weeks because of symptomatic leukemic disease irrespective of the TP53 genotype of the injected MOLM13 cells (Figs. 3B–D and EV2).